Document is current
Any future updates will be listed below
-
Authors
Jo, Suin https://orcid.org/0000-0002-7575-9017
Li, Lijin https://orcid.org/0000-0001-6203-8854
Thakur, Chandrani https://orcid.org/0000-0003-2833-0610
Telfer, Kevin A.
Sultan, Hussein https://orcid.org/0000-0003-4067-8169
Ohara, Ray A. https://orcid.org/0000-0001-7897-3169
He, Michelle https://orcid.org/0009-0004-1579-5595
Nam, Giri
Chen, Jing
Ou, Feiya https://orcid.org/0000-0001-8289-4025
Draghi, Monia
Valiante, Nicholas M.
Schreiber, Robert D. https://orcid.org/0000-0003-1590-2341
Randolph, Gwendalyn J. https://orcid.org/0000-0001-9045-1195
Saligrama, Naresha https://orcid.org/0000-0003-2526-7150
Murphy, Theresa L.
Gillanders, William E. https://orcid.org/0000-0002-0465-3071
Murphy, Kenneth M. https://orcid.org/0000-0002-3505-9630
- License Information
-
More Information
Article History
Received: 1 May 2025
Accepted: 3 March 2026
First Online: 15 April 2026
Competing interests
: N.M.V. holds stock in Glyde Bio and Innovac Therapeutics. G.J.R. reports a patent pending (PCT/US2025/038758) and an associated product licensed to Leinco Technologies. R.D.S. is a co-founder, scientific advisory board member and stockholder of Asher Biotherapeutics, and a scientific advisory board member of A2 Biotherapeutics, BioLegend (Revvity) and Neuvogen. Work in the Schreiber laboratory was supported by research grants from the National Cancer Institute and the Parker Institute for Cancer Immunotherapy. The other authors declare no competing interests.
